Redcare Pharmacy NV

SWX:RDC Stock Report

Market Cap: CHF 1.2b

Redcare Pharmacy Valuation

Is RDC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RDC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RDC (CHF60.25) is trading below our estimate of future cash flow value (CHF259.61)

Significantly Below Future Cash Flow Value: RDC is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RDC?

Key metric: As RDC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for RDC. This is calculated by dividing RDC's market cap by their current revenue.
What is RDC's PS Ratio?
PS Ratio0.4x
Sales€3.07b
Market Cap€1.33b

Price to Sales Ratio vs Peers

How does RDC's PS Ratio compare to its peers?

The above table shows the PS ratio for RDC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.4x
DOCM DocMorris
0.4x8.97%CHF 395.7m
9627 Ain Holdings
0.3x7.37%JP¥191.6b
3148 Create SD Holdings
0.4xn/aJP¥209.3b
DCP Dis-Chem Pharmacies
0.7x9.12%R29.2b
RDC Redcare Pharmacy
0.4x10.60%CHF 1.3b

Price-To-Sales vs Peers: RDC is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does RDC's PS Ratio compare vs other companies in the European Consumer Retailing Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
RDC 0.4xIndustry Avg. 0.4xNo. of Companies13PS00.40.81.21.62+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: RDC is expensive based on its Price-To-Sales Ratio (0.4x) compared to the European Consumer Retailing industry average (0.4x).

Price to Sales Ratio vs Fair Ratio

What is RDC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RDC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate RDC's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RDC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 60.25
CHF 73.76
+22.42%
18.88%CHF 94.44CHF 50.92n/a9
Jun ’27CHF 40.32
CHF 67.93
+68.48%
26.10%CHF 90.54CHF 36.58n/a9
May ’27CHF 44.86
CHF 67.93
+51.42%
26.49%CHF 90.81CHF 36.69n/a9
Apr ’27CHF 29.80
CHF 80.92
+171.53%
34.11%CHF 137.49CHF 36.66n/a9
Mar ’27CHF 61.00
CHF 115.09
+88.67%
29.63%CHF 182.68CHF 67.59n/a9
Feb ’27CHF 61.00
CHF 120.87
+98.15%
30.68%CHF 183.76CHF 67.99n/a9
Jan ’27n/a
CHF 133.60
0%
29.66%CHF 200.28CHF 69.25n/a8
Dec ’26n/a
CHF 135.68
0%
28.14%CHF 198.42CHF 68.61n/a9
Nov ’26n/a
CHF 140.20
0%
28.33%CHF 198.55CHF 76.08n/a9
Oct ’26n/a
CHF 143.63
0%
29.08%CHF 199.91CHF 76.60n/a8
Sep ’26n/a
CHF 144.15
0%
29.08%CHF 200.63CHF 76.88n/a8
Aug ’26n/a
CHF 151.79
0%
23.27%CHF 198.47CHF 76.05n/a9
Jul ’26CHF 85.74
CHF 157.07
+83.19%
20.49%CHF 200.67CHF 88.15n/a10
Jun ’26CHF 107.71
CHF 157.24
+45.98%
19.52%CHF 199.54CHF 87.65CHF 40.3211
May ’26CHF 122.76
CHF 158.56
+29.17%
19.74%CHF 200.24CHF 87.96CHF 44.8611
Apr ’26n/a
CHF 158.55
0%
19.38%CHF 204.49CHF 88.87CHF 29.8012
Mar ’26CHF 110.25
CHF 149.11
+35.26%
20.62%CHF 189.14CHF 79.59CHF 61.0012
Feb ’26CHF 117.60
CHF 150.69
+28.14%
20.62%CHF 191.15CHF 80.43CHF 61.0012
Jan ’26CHF 125.53
CHF 148.20
+18.06%
20.55%CHF 188.08CHF 79.14n/a12
Dec ’25n/a
CHF 147.92
0%
20.55%CHF 187.72CHF 78.99n/a12
Nov ’25CHF 139.75
CHF 148.19
+6.04%
20.75%CHF 189.35CHF 78.74n/a12
Oct ’25CHF 128.52
CHF 144.49
+12.42%
20.25%CHF 177.97CHF 77.75n/a12
Sep ’25CHF 115.67
CHF 147.03
+27.12%
20.32%CHF 179.75CHF 78.52n/a12
Aug ’25CHF 136.91
CHF 145.81
+6.50%
20.14%CHF 179.12CHF 78.25n/a12
Jul ’25CHF 112.91
CHF 144.32
+27.81%
21.26%CHF 184.24CHF 83.39CHF 85.7412
Jun ’25CHF 111.29
CHF 148.01
+33.00%
21.45%CHF 188.21CHF 85.19CHF 107.7112
CHF 72.34
Fair Value
16.7% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 08:29
End of Day Share Price 2026/06/19 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Redcare Pharmacy NV is covered by 22 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gerhard SchwarzBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Sarah RobertsBarclays